Cannordic enters a reseller agreement for Cannasen®CBD product portfolio with DirectSalud in Spain.
CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby announces that the Company’s subsidiary CanNordic has entered into a reseller agreement with the DirectSalud (“DirectSalud”)
Today, November 5, CS MEDICA announces that the Company has entered into a reseller agreement with DirectSalud. a Spanish and leading international business partnering with worldwide customers.
The reseller agreement
The reseller agreement is non-exclusive and runs initially for 12 months commencing today, October 5 2021, and can be renewed every 12 months. The agreement can be terminated by either party with a 2 months’ notice at any time during the agreement period.
The reseller agreement marks an important step in CS MEDICA's strategic entry into the European- and the international market. DirectSalud will integrate the Cannsen®CBD portfolio into its product portfolio and act as a reseller of the Cannasen®CBD products towards its own extensive international network of pharmaceutical companies. During the agreement, DirectSalud will market CannaSen®CBD products to its customer network.
DirectSalud is located in Spain and is a leading international business partnering with worldwide customers and are distributing products under their own trademarks. DirectSalud specialises in manufacturing and distributing, in terms of private label, of innovative products in the following areas: cosmetic, medical devices, and food supplements. Several of DirectSalud’s customers are currently searching for treatment CBD products and/or medical device CBD products and CS MEDICA believes that the Company can benefit from DirectSalud's extensive network and in order to swiftly get into different markets, both in Europe as well as internationally. For more information about DirectSalud, please visit their website (www.directsalud.es).
This press release contains inside information that CS MEDICA A/S is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 5, 2021 at 14:00 CEST.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.